Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; A preliminary clinical study

Duman B. B., Kara B., KARA İ. O., Demiryurek H., Aksungur E.

JOURNAL OF BUON, vol.16, no.4, pp.759-764, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 4
  • Publication Date: 2011
  • Journal Name: JOURNAL OF BUON
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.759-764
  • Çukurova University Affiliated: Yes

Abstract

Purpose: Sorafenib has been found to have significant clinical activity against hepatocellular carcinoma (HCC). Hand-foot skin syndrome (HFS) has been described with the usage of sorafenib. It is a dose-limiting toxicity and may lead to compromised efficacy because of dose reduction.